ArticleAsian Pacific journal of cancer prevention : APJCP2024
Predictors for Disease-Free and Progression-Free Survivals in Metabolic Responders and Non-Responder on Follow-Up 18FDG PET/CT after Chemoradiation in Patients With Nasopharyngeal Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine disease free survival (DFS) and progression free survival (PFS) and their predictors in patients with nasopharyngeal cancer (NPC) having achieved complete (CMR) and partial metabolic response (PMR) on post-chemoradiation (CRT) 18FDG PET/CT. MATERIALS AND
methodsRetro-prospective study conducted at PET/CT Section of JCIA accredited healthcare facility of Pakistan. Total 73 patients of NPC patients who had baseline and post-CRT 18FDG PET/CT were included and prospectively followed till predefined study end points of recurrence or disease progression or death from April-2016 till January 2024. Based on CMR on post-CRT 18FDG PET/CT, 45 patients labelled as responders while 28 with PMR as non-responders. Using logistic regression and ROC analysis, the predictors of recurrence and disease progression were analyzed in both groups. Kaplan Meier's survival plots were analyzed to measure DFS in responders and PFS in non-responders respectively.
resultsBody mass index (BMI), SUVmax and Stage-IV disease were found significantly higher in non-responder group. DFS in responders was significantly higher than PFS in non-responder (60.157 month ± 8.047 Vs 8.145 months ± 1.851). DFS was seen in 84% of responder group with 16% recurrence (7/45). Baseline SUVmax >14.2 and primary tumor size (PTS) > 41 mm were found significant predictors of recurrence in responder group. In the non-responder group, the PFS was found in 54% patients while 46% patients (n=13/28; 2 expired) had disease progression. No significant predictor was found for PFS in the non-responder group. In DFS the mean survival was significantly higher in patients with SUVmax ≤14.2 versus >14.2 (Mean Survival 67.390 vs. 38.283 months; Logrank 9.899; p=0.0017*). However, near significant difference was observed in non-responder group in their PFS at SUVmax ≤11.9 vs. >11.9 (Mean Survival 10.00 vs. 7.05 months; Logrank=3.096; p=0.0798).
conclusion18FDG PET/CT scan precisely stratifies the treated NPC patients into responders having longer DFS and non-responders having shorter PFS. Higher BMI, SUVmax of primary tumor and metastatic disease were found to have significant association in non-responders. In responders, PTS >41 mm and its SUVmax >14.2 were found significant predictors of recurrence. In non-responders, SUVmax >11.9 was found to have near significant association with disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.